No Data
Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,010
Weight-loss version of semaglutide launched in the Chinese market! novo-nordisk a/s (NVO.US) unlocks new growth engine.
novo-nordisk a/s launched Wegovy in china, with prices lower than in the usa; this is an important step for the company to intensify its investment in the rapidly growing market in china.
Top Gap Ups and Downs on Monday: TSLA, SMCI, LYFT and More
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten
Eli Lilly and Co Options Spot-On: On November 18th, 107.32K Contracts Were Traded, With 373.69K Open Interest
MonkeyGee : maybe gap down
Stock_Drift : Maybe…gap, gap, all around.